JP2018502915A - 炎症及び疼痛の治療のための組成物及び方法 - Google Patents
炎症及び疼痛の治療のための組成物及び方法 Download PDFInfo
- Publication number
- JP2018502915A JP2018502915A JP2017553470A JP2017553470A JP2018502915A JP 2018502915 A JP2018502915 A JP 2018502915A JP 2017553470 A JP2017553470 A JP 2017553470A JP 2017553470 A JP2017553470 A JP 2017553470A JP 2018502915 A JP2018502915 A JP 2018502915A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- administration
- formula
- composition
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clc(cccc1Cl)c1NC1=NCCN1 Chemical compound Clc(cccc1Cl)c1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N CCOC(c(cc1)ccc1N)=O Chemical compound CCOC(c(cc1)ccc1N)=O BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/126—Acids containing more than four carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
- C07C57/12—Straight chain carboxylic acids containing eighteen carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
- C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
本出願は、2015年1月6日出願のインド仮特許出願第89/CHE/2015号の利益を主張するものであり、その開示全体があらゆる目的に依拠し、引用することにより本出願の一部をなす。
RHは、独立して、カプロン酸、カプリル酸、カプリン酸、ラウリン酸、ミリスチン酸、ミリストレイン酸、パルミチン酸、パルミトレイン酸、ステアリン酸、オレイン酸、エライジン酸、リノール酸、リノレン酸、リノールエライジン酸又はアラキドン酸を表す。
RHは、独立して、
RHは、独立して、
RHは、独立して、
有化合物の塩の形の化合物である。しかしながら、ある場合には、例えば環境のpHに応じて、該組成物は、プリロカインと酸部分RHとの混合物の形態であってよい。また本発明は、式IVの組成物と薬学的に許容される賦形剤とを含む医薬組成物を提供する。
RHは、独立して、
本明細書において使用される以下の用語及び語句は、以下に記載の意味を有するものとする。他に定義されない限り、本明細書において使用される全ての技術用語及び科学用語は、当業者により通常理解されるものと同じ意味を有する。
に対象の組成物の1つ以上を投与することを含む。望まない病態(例えば、宿主動物の疾患又は他の望まない状態)が臨床的に表れる前に投与する場合、この処置は予防であり、すなわち望まない病態の発症から宿主を保護し、一方、望まない病態が現れた後に投与する場合、この処置は治療である(すなわち、既存の望まない病態又はその副作用を減少、改善、又は安定化させることを目的とする)。
物又は他の封入材の血漿濃度を参照して決定することができる。例えば、最大血漿濃度(Cmax)及び0時間から無限時間までの血漿濃度時間曲線下面積を使用することができる。
断に左右される。したがって、患者間のばらつきがあるため、上記の投与量はガイドラインであり、医師は、医師自身が患者に適切と考える治療を実現するために薬物の用量を決めることができる。所望の治療の程度を考慮すると、医師は患者の年齢、既存の疾患の有無、及び他の疾患の有無等の種々の因子の均衡を保つようにしなければならない。
罹患している場合、又は担当医が決定した通りの組織若しくは器官の表面に医薬を最も良好に塗布する場合に局所投与を提示することもできる。例えば、標的組織又は器官に高用量を必要とするときに局部(Localized)投与を提示することもできる。頬内投与において、活性組成物は、従来の方法で配合された錠剤又はトローチ剤の形態をとることができる。
例として、酸加水分解性デンプン、膨潤性デンプン、例えばデンプングリコール酸ナトリウム、及びそれらの誘導体、並びにそれらの混合物が挙げられるが、これらに限定されない。適切な膨潤性架橋ポリマーの例として、架橋ポリビニルピロリドン、架橋寒天、及び架橋カルボキシメチルセルロースナトリウム、及びそれらの混合物が挙げられるが、これらに限定されない。
ー崩壊剤を含有する。
、ペッサリー、タンポン、クリーム、ゲル、ペースト、フォーム、又は噴霧配合物がある。
る技術である。イオン導入膜の一例として、Theeuwesの米国特許第5,080,646号が挙げられる。イオン導入が皮膚を通して分子輸送を高める主な機序は、(a)荷電したイオンは同じ電荷の電極に反発すること、(b)電場が加えられると、対イオンが優先的に流れることで荷電した孔を通して生じる溶媒の対流の動きである電気浸透、又は(c)電流を印加することによる皮膚透過性の増大である。
RHは、独立して、カプロン酸、カプリル酸、カプリン酸、ラウリン酸、ミリスチン酸、ミリストレイン酸、パルミチン酸、パルミトレイン酸、ステアリン酸、オレイン酸、エライジン酸、リノール酸、リノレン酸、リノールエライジン酸又はアラキドン酸を表す。
RHは、独立して、
RHは、独立して、
応じて、該組成物は、ベンゾカインとRHによって表される酸部分との混合物の形であってよい。また本発明は、式IIIの組成物と薬学的に許容される賦形剤とを含む医薬組成物を提供する。
RHは、独立して、
パルミトレイン酸、ステアリン酸、オレイン酸、エライジン酸、リノール酸、リノレン酸、リノールエライジン酸又はアラキドン酸を表す。
RHは、独立して、
フロエート、メチルフロエート、エチルフロエート、アミノカプロン酸、カプロン酸、カプリル酸、カプリン酸、ラウリン酸、ミリスチン酸、ミリストレイン酸、パルミチン酸、パルミトレイン酸、ステアリン酸、オレイン酸、エライジン酸、リノール酸、リノレン酸、リノールエライジン酸又はアラキドン酸を表す。
式I及び式IIの化合物を製造するために有用な合成経路の例を以下の実施例に記載し、スキーム1及びスキーム2に一般化する。
スキーム1:
で5時間にわたって撹拌した。その溶液を室温に冷却し、溶媒を減圧下で蒸発させ、ヘキサンと同時蒸発乾固させ、ヘキサン類中に溶解させ、24時間にわたって静置して沈殿した固体を濾過し、乾燥してCLX−SYN−G177C−5−1A(6.1g、69%)を得た。
本開示は、特に神経疾患及びその合併症を治療するための組成物及び方法を提供する。本開示の特定の実施形態について詳述したが、上記の明細書は例示的なものであり、制限するものではない。本明細書の系及び方法の多くの変形例について、本明細書を検討すれば当業者には明らかとなるであろう。特許請求した系及び方法の全範囲は、特許請求の範囲とその等価物の全範囲、及び明細書とそのような変形例を参照して決定するものとする。
上記に挙げたものを含む本明細書で言及した全ての刊行物及び特許は、各々の刊行物又は特許が詳細にかつ個々に参照により引用されると示されているかのように、その内容全体を引用することにより本明細書の一部をなす。矛盾する場合、本明細書における任意の定義を含む本出願に従うものとする。
Claims (10)
- 式II:
RHは、独立して、1−ヒドロキシ−2−ナフトエ酸、2,2−ジクロロ酢酸、2−ヒドロキシエタンスルホン酸、2−オキソグルタル酸、4−アセトアミド安息香酸、4−アミノサリチル酸、酢酸、アジピン酸、アスコルビン酸、アスパラギン酸、ベンゼンスルホン酸、安息香酸、ショウノウ酸、カンファー−10−スルホン酸、カプリン酸(デカン酸)、カプロン酸(ヘキサン酸)、カプリル酸(オクタン酸)、炭酸、ケイ皮酸、クエン酸、シクラミン酸、ドデシル硫酸、エタン−1,2−ジスルホン酸、エタンスルホン酸、ギ酸、フマル酸、ガラクタル酸、ゲンチシン酸、グルコヘプトン酸、グルコン酸、グルクロン酸、グルタミン酸、グルタル酸、グリセロリン酸、グリコール酸、馬尿酸、臭化水素酸、イソ酪酸、乳酸、ラクトビオン酸、ラウリン酸、マレイン酸、リンゴ酸、マロン酸、マンデル酸、メタンスルホン酸、ナフタレン−1,5−ジスルホン酸、ナフタレン−2−スルホン酸、ニコチン酸、硝酸、オレイン酸、シュウ酸、パルミチン酸、パモ酸、リン酸、プロピオン酸、ピログルタミン酸、サリチル酸、セバシン酸、ステアリン酸、コハク酸、硫酸、酒石酸、チオシアン酸、トルエンスルホン酸、ウンデシレン酸、n−アセチルシステイン(nac)、フロエート、メチルフロエート、エチルフロエート、アミノカプロン酸、カプロン酸、カプリル酸、カプリン酸、ラウリン酸、ミリスチン酸、ミリストレイン酸、パルミチン酸、パルミトレイン酸、ステアリン酸、オレイン酸、エライジン酸、リノール酸、リノレン酸、リノールエライジン酸又はアラキドン酸を表す)の化合物並びにその薬学的に許容される水和物、溶媒和物、プロドラッグ、鏡像異性体及び立体異性体。 - 請求項1に記載の化合物と薬学的に許容される担体とを含む医薬組成物。
- 請求項2に記載の化合物と薬学的に許容される担体とを含む医薬組成物。
- 経口投与、遅延放出若しくは徐放、経粘膜投与、シロップ、粘膜付着剤、口腔用製剤、粘膜付着性錠剤、局所投与、非経口投与、注射、皮下投与、経口溶液、経直腸投与、頬内投与、又は経皮投与により治療を必要とする患者に有効な投与量で基礎にある病因を治療するために配合される、請求項3に記載の医薬組成物。
- 経口投与、遅延放出若しくは徐放、経粘膜投与、シロップ、粘膜付着剤、口腔用製剤、粘膜付着性錠剤、局所投与、非経口投与、注射、皮下投与、経口溶液、経直腸投与、頬内投与、又は経皮投与により治療を必要とする患者に有効な投与量で基礎にある病因を治療するために配合される、請求項4に記載の医薬組成物。
- 炎症媒介性の疼痛の治療用に配合されている、請求項5に記載の化合物及び組成物。
- 炎症媒介性の疼痛の治療用に配合されている、請求項6に記載の化合物及び組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN89/CHE/2015 | 2015-01-06 | ||
IN89CH2015 | 2015-01-06 | ||
PCT/IN2015/000199 WO2016110865A1 (en) | 2015-01-06 | 2015-05-07 | Compositions and methods for the treatment of inflammation and pain |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020002379A Division JP2020100623A (ja) | 2015-01-06 | 2020-01-09 | 炎症及び疼痛の治療のための組成物及び方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018502915A true JP2018502915A (ja) | 2018-02-01 |
JP2018502915A5 JP2018502915A5 (ja) | 2018-06-14 |
JP6679616B2 JP6679616B2 (ja) | 2020-04-22 |
Family
ID=53776913
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017553470A Active JP6679616B2 (ja) | 2015-01-06 | 2015-05-07 | 炎症及び疼痛の治療のための組成物及び方法 |
JP2020002379A Pending JP2020100623A (ja) | 2015-01-06 | 2020-01-09 | 炎症及び疼痛の治療のための組成物及び方法 |
JP2022160443A Pending JP2022191331A (ja) | 2015-01-06 | 2022-10-04 | 炎症及び疼痛の治療のための組成物及び方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020002379A Pending JP2020100623A (ja) | 2015-01-06 | 2020-01-09 | 炎症及び疼痛の治療のための組成物及び方法 |
JP2022160443A Pending JP2022191331A (ja) | 2015-01-06 | 2022-10-04 | 炎症及び疼痛の治療のための組成物及び方法 |
Country Status (9)
Country | Link |
---|---|
US (3) | US10227301B2 (ja) |
EP (1) | EP3242869B1 (ja) |
JP (3) | JP6679616B2 (ja) |
CN (2) | CN110845355A (ja) |
CA (1) | CA2973178C (ja) |
DK (1) | DK3242869T3 (ja) |
ES (1) | ES2905771T3 (ja) |
SG (1) | SG11201705524SA (ja) |
WO (1) | WO2016110865A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016110865A1 (en) * | 2015-01-06 | 2016-07-14 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and pain |
IL290150B2 (en) * | 2016-12-26 | 2024-03-01 | Cellix Bio Private Ltd | Compounds and methods for treating chronic pain |
CN109896992A (zh) * | 2017-12-08 | 2019-06-18 | 武汉软件工程职业学院 | 制备离子液体的方法及其应用 |
WO2019217536A1 (en) * | 2018-05-08 | 2019-11-14 | University Of Connecticut | Long-acting local anesthetic formulation |
WO2023073574A1 (en) * | 2021-10-28 | 2023-05-04 | Cellix Bio Private Limited | Process for the preparation of piperidine carboxamides salt forms and thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009100441A2 (en) * | 2008-02-08 | 2009-08-13 | Impax Laboratories, Inc. | Depot formulations |
WO2014091384A2 (en) * | 2012-12-12 | 2014-06-19 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
WO2014160026A2 (en) * | 2013-03-14 | 2014-10-02 | Endo Pharmaceuticals Solutions Inc. | Implantable drug delivery compositions comprising sugar-based sorption enhancers and methods of treatment thereof |
Family Cites Families (160)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2807644A (en) | 1954-08-20 | 1957-09-24 | Parke Davis & Co | Pantethine inhibitors |
DE1205972B (de) | 1963-08-20 | 1965-12-02 | Merck Ag E | Verfahren zur Herstellung eines Liponsaeure-derivates |
FR1434130A (fr) * | 1964-07-31 | 1966-04-08 | Dausse Lab | Sels de l'acide nu-cyclohexylsulfamique et leur procédé de préparation |
US4011342A (en) | 1971-06-02 | 1977-03-08 | Seperic | Method and composition for the treatment of hypertension with ortho-disubstituted arylguanidines |
GB1356470A (en) | 1971-06-02 | 1974-06-12 | Seperic | Ortho-disubstituted aryl-guanidines process for their preparation and applications thereof |
AU514991B2 (en) | 1976-05-26 | 1981-03-12 | Commonwealth Of Australia, The | Pharmaceutical compositions containing antiinflammatory analgesic compounds |
JPS5412340A (en) | 1977-06-27 | 1979-01-30 | Daito Koeki | Process for preparing phenylacetate derivative |
JPS5677259A (en) | 1979-11-29 | 1981-06-25 | Nippon Chemiphar Co Ltd | N-pyridoxyl 5,8,11,14,17-eicosapentaenoic acid amide, and its preparation |
JPS57500432A (ja) | 1980-03-20 | 1982-03-11 | ||
US4404366A (en) | 1980-05-06 | 1983-09-13 | Miles Laboratories, Inc. | Beta-galactosyl-umbelliferone-labeled hapten conjugates |
US4412992A (en) | 1980-07-21 | 1983-11-01 | Biorex Laboratories Limited | 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith |
US4440763A (en) | 1981-03-18 | 1984-04-03 | Block Drug Company, Inc. | Use of 4-aminosalicyclic acid as an anti-inflammatory agent |
IT1190727B (it) | 1982-03-10 | 1988-02-24 | Ausonia Farma Srl | Composto ad attivita' analgesica,antiinfiammatoria e mucoregolatrice procedimento per la sua preparazione e relative composizioni farmaceutiche |
FR2528038B2 (fr) | 1982-06-04 | 1985-08-09 | Lafon Labor | Derives de benzhydrylsulfinylacetamide et leur utilisation en therapeutique |
US4564628A (en) | 1983-01-03 | 1986-01-14 | Nelson Research & Development Co. | Substituted 2-aminotetralins |
US5104887A (en) | 1983-02-04 | 1992-04-14 | University Of Iowa Research Foundation | Topical ophthalmic imino substituted 2-imino-3-methyl-delta4-1,3,4-thiadiazoline-5-sulfonamides carbonic anhydrase inhibitors |
EP0151110B1 (en) | 1983-08-01 | 1989-03-01 | Astra Läkemedel Aktiebolag | L-n-n-propylpipecolic acid-2,6-xylidide and method for preparing the same |
JPS6089474A (ja) | 1983-10-20 | 1985-05-20 | Toyo Pharma- Kk | モルフイナン誘導体,その製造方法,及び該化合物を含有する抗腫瘍剤 |
IL73293A (en) | 1983-11-04 | 1988-02-29 | Abbott Lab | Methyl 2-(alkanamidoalkylsulfonic)ethylthiophosphonate derivatives |
IT1213132B (it) | 1984-02-02 | 1989-12-14 | Yason Srl | Agente antibroncopneumopatico. |
US4550109A (en) | 1984-05-31 | 1985-10-29 | The Board Of Regents, The University Of Texas System | Lipoidal biopterin compounds |
JPS61277618A (ja) | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
YU213587A (en) | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
US4873259A (en) | 1987-06-10 | 1989-10-10 | Abbott Laboratories | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds |
US5446070A (en) * | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
US5102870A (en) | 1989-04-14 | 1992-04-07 | Schering Ag | Treatment and prevention of oral mucositis with growth factors |
DE69016335T2 (de) | 1989-10-06 | 1995-06-01 | Fujirebio Kk | Pantothensäure Derivate. |
US5242937A (en) | 1990-03-19 | 1993-09-07 | Research Corporation Technologies, Inc. | Topically active ocular thiadiazole sulfonamide carbonic anhydrase inhibitors |
IT1248702B (it) | 1990-06-06 | 1995-01-26 | Yason Srl | Agente antitussivo e mucoregolatore,sua preparazione e composizioni farmaceutiche |
FR2699077B1 (fr) | 1992-12-16 | 1995-01-13 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes. |
FR2707637B1 (fr) | 1993-06-30 | 1995-10-06 | Lafon Labor | Nouveaux dérivés d'acétamide, leur procédé de préparation et leur utilisation en thérapeutique. |
EP0746557A4 (en) | 1994-02-18 | 1997-05-02 | Cell Therapeutics Inc | INTRACELLULAR SIGNALING MEDIATORS |
SE9401727D0 (sv) | 1994-05-18 | 1994-05-18 | Astra Ab | New compounds I |
FR2722199B3 (fr) | 1994-07-11 | 1996-09-06 | Univ Picardie Jules Verne Etab | Derives de l'acide valproique et leurs applications comme medicaments |
US6156777A (en) | 1994-12-15 | 2000-12-05 | Pharmacia & Upjohn Company | Use of pramipexole as a neuroprotective agent |
NZ334389A (en) | 1996-08-28 | 2001-05-25 | Ube Industries | Cyclic amine derivatives |
PL334516A1 (en) | 1996-11-22 | 2000-02-28 | Elan Pharm Inc | N-(aryl/heteroaryl/alkylacetyl)amino cid amides, pharmaceutic agent containing them and method of inhibiting eduction and/or synthesis of beta-amyloid peptide using such compounds |
US6414008B1 (en) | 1997-04-29 | 2002-07-02 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions |
GB9710351D0 (en) | 1997-05-20 | 1997-07-16 | Scotia Holdings Plc | Glucosamine fatty acids |
NZ503513A (en) * | 1997-09-18 | 2004-12-24 | Skyepharma Inc | Sustained-release liposomal anesthetic compositions |
NZ333474A (en) | 1998-01-02 | 1999-06-29 | Mcneil Ppc Inc | A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat |
MXPA00008439A (es) | 1998-02-27 | 2002-04-24 | Sankyo Co | Compuestos amino ciclicos.. |
JP3761324B2 (ja) | 1998-05-15 | 2006-03-29 | ヤンマー農機株式会社 | 乗用田植機 |
US6846495B2 (en) | 1999-01-11 | 2005-01-25 | The Procter & Gamble Company | Compositions having improved delivery of actives |
CZ20013607A3 (cs) | 1999-04-06 | 2002-06-12 | Sepracor Inc. | Farmaceutický prostředek |
US6262118B1 (en) | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
CN1211085C (zh) | 1999-09-29 | 2005-07-20 | 宝洁公司 | 稳定性改善的组合物 |
AU6972901A (en) | 2000-05-31 | 2001-12-11 | Mayo Foundation | Cobalamin compounds useful as cardiovascular agents and as imaging agents |
US6429223B1 (en) | 2000-06-23 | 2002-08-06 | Medinox, Inc. | Modified forms of pharmacologically active agents and uses therefor |
US6602915B2 (en) | 2000-07-27 | 2003-08-05 | Rutgers, The State University Of New Jersey | Therapeutic azo-compounds for drug delivery |
DE60130014T2 (de) | 2000-10-24 | 2008-05-08 | Ajinomoto Co., Inc. | Verfahren zur herstellung der b-form von nateglinid-kristallen |
DE10103506A1 (de) | 2001-01-26 | 2002-08-14 | Ingo S Neu | Pharmazeutische Zusammensetzung zur Behandlung von Multiple Sklerose |
UA81224C2 (uk) | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
FR2827517B1 (fr) | 2001-07-23 | 2003-10-24 | Bioalliance Pharma | Systemes therapeutiques bioadhesifs a liberation prolongee |
CN1612732A (zh) | 2001-08-29 | 2005-05-04 | 恩德制药公司 | 止痛剂和使用方法 |
US7138133B2 (en) | 2001-10-10 | 2006-11-21 | The Procter & Gamble Company | Orally administered liquid compositions |
US20040010038A1 (en) | 2002-02-27 | 2004-01-15 | Eran Blaugrund | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors |
US20030220344A1 (en) | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
AU2003242520A1 (en) | 2002-04-15 | 2003-10-27 | Novartis Ag | Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine |
NZ535692A (en) | 2002-04-16 | 2006-07-28 | Astellas Pharma Inc | Medicament for preventing and/or treating chronic rejection |
US7060725B2 (en) | 2002-05-13 | 2006-06-13 | Janssen Pharmaceutica N.V. | Substituted sulfamate anticonvulsant derivatives |
GB0223224D0 (en) | 2002-10-07 | 2002-11-13 | Novartis Ag | Organic compounds |
US7101912B2 (en) | 2002-12-06 | 2006-09-05 | Xenoport, Inc. | Carbidopa prodrugs and derivatives, and compositions and uses thereof |
PT1587821E (pt) | 2002-12-19 | 2008-09-23 | Scripps Research Inst | Composições e métodos para estabilização da transtirretina e inibição do enrolamento incorrecto da transtirretina |
CA2514948C (fr) | 2003-02-14 | 2013-04-02 | Pierre Fabre Medicament | Utilisation de l'enantiomere (1s, 2r) du milnacipran pour la preparation d'un medicament |
UA81657C2 (ru) | 2003-03-04 | 2008-01-25 | Орто-Макнейл Фармасьютикел, Инк. | Способ получения противосудорожных производных топирамата |
JP2006520335A (ja) | 2003-03-18 | 2006-09-07 | ノバルティス アクチエンゲゼルシャフト | 脂肪酸とアミノ酸を含有する組成物 |
EP1643999B8 (en) | 2003-06-20 | 2012-03-14 | NephroGenex, Inc. | Pyridoxamine for use in the treatment of diabetic nephropathy in type ii diabetes |
EP1660017A4 (en) | 2003-07-29 | 2011-03-09 | Signature R & D Holdings Llc | Amino acid PRODRUGS |
NZ546381A (en) | 2003-10-14 | 2010-01-29 | Xenoport Inc | Crystalline form of gamma-aminobutyric acid analog |
US7470435B2 (en) | 2003-11-17 | 2008-12-30 | Andrx Pharmaceuticals, Llc | Extended release venlafaxine formulation |
CA2547472A1 (en) | 2003-11-28 | 2005-06-09 | Sankyo Company Limited | Cyclic amine derivative having heteroaryl ring |
DE10361259A1 (de) | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes |
CN1248690C (zh) | 2004-03-25 | 2006-04-05 | 华中师范大学 | 一种治疗心血管疾病含盐酸雷诺嗪的口服制剂 |
MXPA06011475A (es) | 2004-04-07 | 2007-04-25 | Univ Georgia Res Found | Profarmacos, composiciones y metodos mutuos de glucosamina y glucosamina/antiinflamatorios. |
MEP25008A (en) | 2004-04-29 | 2010-10-10 | Caldwell Galer Inc | Topical methadone compositions and methods for using the same |
CN1672678A (zh) | 2004-05-03 | 2005-09-28 | 深圳微芯生物科技有限责任公司 | 预防和治疗前列腺疾病的长链脂肪酸天然活性成分的分离、提取和药用制剂的制备和应用 |
NZ551511A (en) | 2004-06-04 | 2010-09-30 | Xenoport Inc | Levodopa prodrugs, and compositions and uses thereof |
CN100455560C (zh) | 2004-06-09 | 2009-01-28 | 中国人民解放军军事医学科学院放射医学研究所 | 含长链脂肪酰基取代的文拉法辛前体药物及其制备方法和用途 |
JP5144277B2 (ja) | 2005-01-14 | 2013-02-13 | カムルス エービー | 局所用生体付着性製剤 |
EP1863433A4 (en) | 2005-03-18 | 2009-09-09 | Ripped Formulations Ltd | COMPOSITIONS AND METHODS FOR INCREASING METABOLISM, HEAT GENERATION AND / OR MUSCLE EDUCATION |
EP1940392A2 (en) | 2005-05-11 | 2008-07-09 | Nycomed GmbH | Combination of the pde4 inhibitor and a tetrahydrobiopterin derivative |
DE102005022276A1 (de) | 2005-05-13 | 2006-11-16 | Ellneuroxx Ltd. | Derivate von Dihydroxyphenylalanin |
JP5319278B2 (ja) * | 2005-05-27 | 2013-10-16 | ロイヤー バイオメディカル, インク. | 生体再吸収性ポリマーマトリックス、ならびにその作製および使用方法 |
US20060270635A1 (en) | 2005-05-27 | 2006-11-30 | Wallace John L | Derivatives of 4- or 5-aminosalicylic acid |
WO2006125293A1 (en) | 2005-05-27 | 2006-11-30 | Antibe Therapeutics Inc. | Derivatives of 4- or 5-aminosalicylic acid |
JPWO2006126676A1 (ja) | 2005-05-27 | 2008-12-25 | 第一三共株式会社 | 置換アルキル基を有する環状アミン誘導体 |
EP1940398A1 (de) | 2005-10-18 | 2008-07-09 | Boehringer Ingelheim International GmbH | Verwendung von pramipexol zur behandlung des moderaten bis schweren restless legs syndroms (rls) |
WO2007086493A1 (ja) | 2006-01-27 | 2007-08-02 | Asahi Kasei Pharma Corporation | 経鼻投与用薬剤 |
WO2007121188A2 (en) | 2006-04-10 | 2007-10-25 | Knopp Neurosciences, Inc. | Compositions and methods of using r(+) pramipexole |
EP1870395A1 (en) | 2006-06-19 | 2007-12-26 | KRKA, D.D., Novo Mesto | Process for preparation of o-desmethylvenlafaxine and its analogue |
EP2046121B1 (en) * | 2006-07-14 | 2012-08-22 | Stiefel Research Australia Pty Ltd | Fatty acid pharmaceutical foam |
US7943666B2 (en) | 2006-07-24 | 2011-05-17 | Trinity Laboratories, Inc. | Esters of capsaicin for treating pain |
US7645767B2 (en) | 2006-08-31 | 2010-01-12 | Trinity Laboratories, Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
TW200817048A (en) | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
CN100573950C (zh) | 2006-12-14 | 2009-12-23 | 财团法人工业技术研究院 | 相变存储装置及其制造方法 |
AU2007333050B2 (en) | 2006-12-14 | 2013-08-29 | Knopp Biosciences Llc | Compositions and methods of using (R)-pramipexole |
CA2673511A1 (en) | 2006-12-22 | 2008-07-03 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
AU2008206486C1 (en) | 2007-01-12 | 2013-09-26 | Biomarin Pharmaceutical Inc. | Tetrahydrobiopterin prodrugs |
ES2319024B1 (es) | 2007-02-13 | 2009-12-11 | Quimica Sintetica, S.A. | Procedimiento para la obtencion de entacapona sustancialmente libre de isomero z, sus intermedios de sintesis y nueva forma cristalina. |
US8519148B2 (en) | 2007-03-14 | 2013-08-27 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
PL2522668T3 (pl) | 2007-05-01 | 2015-07-31 | Concert Pharmaceuticals Inc | Związki morfinanu |
EP1997493A1 (en) | 2007-05-28 | 2008-12-03 | Laboratorios del Dr. Esteve S.A. | Combination of a 5-HT7 receptor ligand and an opioid receptor ligand |
EP2190853A4 (en) | 2007-06-22 | 2011-08-31 | Gluconova Llc | HALOGENIDE-FREE COMPLEXES FROM GLUCOSAMINE AND AN ACIDIC ACID |
US20090075942A1 (en) | 2007-09-13 | 2009-03-19 | Protia, Llc | Deuterium-enriched fosamprenavir |
CN101390854A (zh) | 2007-09-21 | 2009-03-25 | 北京德众万全药物技术开发有限公司 | 一种含有利鲁唑的药用组合物 |
US20090093547A1 (en) * | 2007-10-09 | 2009-04-09 | Sciele Pharma, Inc. | Compositions and Methods for Treating Premature Ejaculation |
WO2009056791A1 (en) | 2007-11-02 | 2009-05-07 | Pliva Hrvatska D.O.O. | Processes for preparing pharmaceutical compounds |
WO2009061934A1 (en) | 2007-11-06 | 2009-05-14 | Xenoport, Inc. | Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain |
US8920843B2 (en) * | 2007-11-07 | 2014-12-30 | Svip5 Llc | Slow release of organic salts of local anesthetics for pain relief |
JP5333972B2 (ja) * | 2007-11-22 | 2013-11-06 | 株式会社 メドレックス | 脂肪酸系イオン液体を有効成分とする外用剤組成物 |
CN101186583B (zh) | 2007-12-20 | 2011-05-11 | 吉林大学 | 2-(2-(2,6-二氯苯基氨基)苯基)醋酸甲酯及其合成方法及其应用 |
US20100081713A1 (en) | 2008-03-19 | 2010-04-01 | CombinatoRx, (Singapore) Pte. Ltd. | Compositions and methods for treating viral infections |
CN101569618B (zh) | 2008-04-30 | 2011-11-09 | 上海医药工业研究院 | 一类长链脂肪酸衍生物在制备预防或治疗前列腺增生疾病的药物组合物中的应用 |
KR100990949B1 (ko) | 2008-06-09 | 2010-10-29 | 엔자이텍 주식회사 | 클로피도그렐 및 그의 유도체의 제조방법 |
PL2315740T3 (pl) | 2008-07-08 | 2018-05-30 | Catabasis Pharmaceuticals, Inc. | Salicylany acetylowane kwasem tłuszczowym i ich zastosowania |
EP2311498A4 (en) * | 2008-08-05 | 2013-07-24 | Medrx Co Ltd | EXTERNAL PREPARATION COMPRISING A FATTY ACID SALT OR A BENZOIC ACID SALT OF A PHARMACOLOGICALLY ACTIVE BASIC COMPONENT, AND PROCESS FOR PRODUCTION THEREOF |
DK2334378T3 (da) | 2008-08-19 | 2014-07-07 | Xenoport Inc | Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse |
NZ591326A (en) | 2008-08-22 | 2012-12-21 | Wockhardt Research Center | An extended release pharmaceutical composition of entacapone or salts thereof |
EP2165706A1 (en) | 2008-09-18 | 2010-03-24 | BioAlliance Pharma | Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers. |
WO2010073124A2 (en) | 2008-12-26 | 2010-07-01 | Actavis Group Ptc Ehf | Processes for preparing highly pure rotigotine or a pharmaceutically acceptable salt thereof |
BRPI0901298A2 (pt) | 2009-04-06 | 2011-01-04 | Ems Sa | derivados ftalimìdicos de compostos antiinflamatórios não-esteróide e/ou moduladores de tnf-(alfa), processo de sua obtenção, composições farmacêuticas contendo os mesmos e seus usos no tratamento de doenças inflamatórias |
CN101559077A (zh) * | 2009-04-16 | 2009-10-21 | 官培龙 | 一种口腔炎症性疾病止痛用含漱液 |
NZ720946A (en) | 2009-04-29 | 2017-09-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
WO2010147666A1 (en) | 2009-06-19 | 2010-12-23 | Memorial Sloan-Kettering Cancer Center | Compounds useful as carbonic anhydrase modulators and uses thereof |
EA201290007A1 (ru) | 2009-08-10 | 2013-01-30 | Беллус Хелс Инк. | Способы, соединения и композиции для доставки 1,3-пропандисульфокислоты |
CN102002053A (zh) | 2009-09-02 | 2011-04-06 | 陕西合成药业有限公司 | 用于治疗的四氢噻吩并吡啶衍生物 |
CN101717392A (zh) | 2009-10-09 | 2010-06-02 | 苏州凯达生物医药技术有限公司 | 一种制备罗替戈汀及其衍生物的方法 |
CN102050815B (zh) | 2009-11-06 | 2014-04-02 | 北京美倍他药物研究有限公司 | 作为前药的达比加群的酯衍生物 |
CN101724934B (zh) | 2009-11-10 | 2012-07-04 | 东华大学 | 一种用于治疗皮肤炎症和疼痛的药用纤维及其制备和应用 |
ES2364011B1 (es) | 2009-11-20 | 2013-01-24 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. |
US20110172240A1 (en) | 2010-01-08 | 2011-07-14 | Milne Jill C | Fatty acid fumarate derivatives and their uses |
US9062094B2 (en) | 2010-01-22 | 2015-06-23 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
RU2436772C2 (ru) | 2010-01-28 | 2011-12-20 | Закрытое акционерное общество "НПК ЭХО" | 4[(4'-никотиноиламино)бутироиламино]бутановая кислота, проявляющая ноотропную активность, и способ ее получения |
US20130190327A1 (en) | 2010-02-26 | 2013-07-25 | Catabasis Pharmaceuticals Inc | Bis-fatty acid conjugates and their uses |
JP5412340B2 (ja) | 2010-03-19 | 2014-02-12 | 本田技研工業株式会社 | 車両の視認窓 |
SG185754A1 (en) | 2010-06-08 | 2012-12-28 | Mahesh Kandula | Cysteamine derivatives and their use in the treatment of nash |
EA025640B1 (ru) | 2010-07-12 | 2017-01-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Водная композиция, содержащая бромгексин |
US20120046272A1 (en) | 2010-08-23 | 2012-02-23 | Grunenthal Gmbh | Novel Therapeutic Compounds |
WO2012027543A1 (en) | 2010-08-25 | 2012-03-01 | Teva Pharmaceuticals Usa, Inc. | Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof |
CN101921245B (zh) | 2010-08-30 | 2012-04-18 | 中国人民解放军军事医学科学院卫生学环境医学研究所 | 抑制碳酸酐酶ⅱ的磺胺类化合物及合成方法与用途 |
NO2632451T3 (ja) | 2010-10-29 | 2018-03-17 | ||
EP2450039A1 (en) | 2010-11-08 | 2012-05-09 | PAION UK Ltd. | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
WO2012115695A1 (en) | 2011-02-25 | 2012-08-30 | Catabasis Pharmaceuticals, Inc. | Bis-fatty acid conjugates and their uses |
CA2860373C (en) * | 2011-04-29 | 2017-08-15 | Moberg Pharma Ab | Pharmaceutical compositions comprising a local anaesthetic such as bupivacaine for local administration to the mouth or throat |
WO2013008182A1 (en) | 2011-07-10 | 2013-01-17 | Mahesh Kandula | Prodrugs of gaba analogs |
CN102336767A (zh) | 2011-07-11 | 2012-02-01 | 华东理工大学 | 制备高纯度手性α-取代-6,7-二氢噻吩并[3,2-c]吡啶衍生物的方法 |
WO2013017974A1 (en) | 2011-07-30 | 2013-02-07 | Mahesh Kandula | Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases |
WO2013024376A1 (en) | 2011-08-16 | 2013-02-21 | Mahesh Kandula | Compositions and methods for the treatment of atherothrombosis |
WO2013027150A1 (en) | 2011-08-21 | 2013-02-28 | Mahesh Kandula | Compositions and methods for the treatment of parkinson's disease |
CN102633799B (zh) | 2012-04-10 | 2014-06-25 | 凯莱英医药集团(天津)股份有限公司 | 一种从消旋体中间体拆分路线合成二盐酸沙丙蝶呤的方法 |
WO2013168022A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treating atherothrombosis |
WO2013167993A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological degenerative disorders |
US20150133533A1 (en) | 2012-05-08 | 2015-05-14 | Mahesh Kandula | Compositions and methods for the treatment of cough |
WO2013167996A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
SG11201407326XA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of mucositis |
WO2014061497A1 (ja) * | 2012-10-16 | 2014-04-24 | コニカミノルタ株式会社 | フィルムミラー及び太陽熱発電用反射装置 |
WO2014174425A2 (en) | 2013-04-24 | 2014-10-30 | Mahesh Kandula | Compositions and methods for the treatment of orthostasis and neurological diseases |
AU2014276346A1 (en) | 2013-06-04 | 2015-12-24 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
WO2016110865A1 (en) * | 2015-01-06 | 2016-07-14 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and pain |
-
2015
- 2015-05-07 WO PCT/IN2015/000199 patent/WO2016110865A1/en active Application Filing
- 2015-05-07 EP EP15745569.2A patent/EP3242869B1/en active Active
- 2015-05-07 SG SG11201705524SA patent/SG11201705524SA/en unknown
- 2015-05-07 CN CN201910996145.4A patent/CN110845355A/zh active Pending
- 2015-05-07 DK DK15745569.2T patent/DK3242869T3/da active
- 2015-05-07 JP JP2017553470A patent/JP6679616B2/ja active Active
- 2015-05-07 CA CA2973178A patent/CA2973178C/en active Active
- 2015-05-07 US US14/647,130 patent/US10227301B2/en active Active
- 2015-05-07 ES ES15745569T patent/ES2905771T3/es active Active
- 2015-05-07 CN CN201580077468.3A patent/CN107428697A/zh active Pending
- 2015-07-22 US US14/805,507 patent/US10343994B2/en active Active
-
2016
- 2016-03-29 US US15/083,319 patent/US9464051B2/en active Active
-
2020
- 2020-01-09 JP JP2020002379A patent/JP2020100623A/ja active Pending
-
2022
- 2022-10-04 JP JP2022160443A patent/JP2022191331A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009100441A2 (en) * | 2008-02-08 | 2009-08-13 | Impax Laboratories, Inc. | Depot formulations |
WO2014091384A2 (en) * | 2012-12-12 | 2014-06-19 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
WO2014160026A2 (en) * | 2013-03-14 | 2014-10-02 | Endo Pharmaceuticals Solutions Inc. | Implantable drug delivery compositions comprising sugar-based sorption enhancers and methods of treatment thereof |
Also Published As
Publication number | Publication date |
---|---|
US10343994B2 (en) | 2019-07-09 |
CN110845355A (zh) | 2020-02-28 |
ES2905771T3 (es) | 2022-04-12 |
NZ734324A (en) | 2021-06-25 |
EP3242869B1 (en) | 2021-10-27 |
SG11201705524SA (en) | 2017-08-30 |
DK3242869T3 (da) | 2022-01-31 |
JP2020100623A (ja) | 2020-07-02 |
WO2016110865A1 (en) | 2016-07-14 |
US20180155287A1 (en) | 2018-06-07 |
JP2022191331A (ja) | 2022-12-27 |
CA2973178C (en) | 2022-11-01 |
EP3242869A1 (en) | 2017-11-15 |
CN107428697A (zh) | 2017-12-01 |
US20160194287A1 (en) | 2016-07-07 |
CA2973178A1 (en) | 2016-07-14 |
US10227301B2 (en) | 2019-03-12 |
US9464051B2 (en) | 2016-10-11 |
JP6679616B2 (ja) | 2020-04-22 |
US20160207886A1 (en) | 2016-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020100623A (ja) | 炎症及び疼痛の治療のための組成物及び方法 | |
JP2015518855A (ja) | 粘膜炎の治療のための組成物および方法 | |
KR20200118128A (ko) | 항무스카린제 또는 항콜린제 및 리포산의 조합 및 이의 용도 | |
RU2749189C2 (ru) | Композиции и способы лечения ксеростомии | |
JP2015518855A5 (ja) | ||
JP2017531649A (ja) | 多発性硬化症の治療のための組成物及び方法 | |
KR102567089B1 (ko) | 곰팡이 감염의 치료를 위한 조성물 및 방법 | |
JP2016508956A (ja) | 局所疼痛の治療のための組成物と治療法 | |
US9840472B2 (en) | Compositions and methods for the treatment of mucositis | |
JP2019535795A (ja) | 口腔感染症の処置のための組成物及び方法 | |
JP6698669B2 (ja) | 粘膜炎の治療のための組成物及び方法 | |
JP2015521174A (ja) | 糖尿病の治療のための組成物および方法 | |
JP2015533114A (ja) | 神経疾患の治療のための組成物及び方法 | |
JP2019524796A (ja) | 過敏性腸症候群の処置のための組成物及び方法 | |
US11168065B2 (en) | Compositions and methods for the treatment of mucositis | |
JP2018532704A (ja) | パーキンソン病の治療のための組成物及び方法 | |
NZ734324B2 (en) | Compositions and methods for the treatment of inflammation and pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180507 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180507 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20181227 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190123 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190423 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20190520 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190624 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190723 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190724 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20190724 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190910 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200110 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20200203 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200310 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200318 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6679616 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |